Treatment options and strategies for acute severe pulmonary embolism

Internal Medicine Journal

Volumn 38, Issue 8, 2008, Pages 657-667

  Hamilton Craig, C R ^a,c   McNeil, K ^a   Dunning, J ^b   Walters, D L ^a   Slaughter, R ^a   Kermeen, F ^a  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

^b PAPWORTH HOSPITAL   (United Kingdom)

^c NONE   (Australia)

Author keywords

Pulmonary embolism; Pulmonary hypertension

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; BOSENTAN; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; SILDENAFIL; UROKINASE; WARFARIN;

ACUTE DISEASE; ALGORITHM; ANTICOAGULANT THERAPY; BLOOD CLOT LYSIS; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL PRACTICE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONSERVATIVE TREATMENT; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EMBOLECTOMY; ENDARTERECTOMY; FIBRINOLYTIC THERAPY; FOLLOW UP; GENETIC PREDISPOSITION; HEART RIGHT VENTRICLE; HEART VENTRICLE SIZE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; LUNG ANGIOGRAPHY; LUNG EMBOLISM; LUNG VENTILATION PERFUSION RATIO; MAGNETIC RESONANCE ANGIOGRAPHY; OBESITY; ORAL CONTRACEPTION; PATIENT MONITORING; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; THORAX PAIN; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ADULT; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 51349142280     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01671.x     Document Type: Review

References (39)

1. Dalen JE, Alper JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975 17 : 259 70.
2. Donnamaria V, Palla A, Giuntini C. Gender, age and clinical signs of patients suspected of pulmonary embolism. Respiration 1994 61 7.
3. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999 353 : 1386 9.
4. Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser K, Rauber K et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism (MAPPET trial). Circulation 1997 96 : 882 8.
5. Barritt DW, Jordan SE. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960 1 : 1309 12.
6. Task Force on Pulmonary Embolism, European Society of Cardiology. Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 2000 21 : 1301 36.
7. Fedullo P, Tapson V. The evaluation of suspected pulmonary embolism. N Engl J Med 2003 349 : 1247 56.
8. Tapson VF, Carroll BA, Davidson BL, Elliot CG, Fedullo PF, Hales CA et al. The diagnostic approach to acute venous thromboembolism: clinical practice guideline. Am J Respir Crit Care Med 1999 160 : 1043 66.
9. Wood K. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002 121 : 877 905.
10. Uflacker R. Interventional therapy for pulmonary embolism. J Vasc Interv Radiol 2001 21 : 147 64.
11. Geibel A, Zehender M, Kasper W, Olschewski M, Klima C, Konstantinides S. Prognostic value of the ECG on admission in patients with acute major pulmonary embolism. Eur Respir J 2005 25 : 843 8.
12. Ullman E, Brady WJ, Perron AD, Chan T, Mattu A. Electrocardiographic manifestations of pulmonary embolism. Am J Emerg Med 2001 19 : 514 19.
13. Konstantinides S. Pulmonary embolism: impact of right ventricular dysfunction. Curr Opin Cardiol 20 : 496 501.
14. Gulba DC, Schmid C, Borst HG, Lichtlen P, Dietz R, Luft FC. Medical compared with surgical treatment for massive pulmonary embolism. Lancet 1994 343 : 576 7.
15. Kasper W, Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser KD et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997 30 : 1165 71.
16. Schoepf UJ, Kucher N, Kipfmueller F, Quiroz R, Costello P, Goldhaber SZ. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 2004 110 : 3276 80.
17. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis. Circulation 2004 110 : 744 9.
18. Anderson B. Echocardiography - The Normal Examination and Echocardiographic Measurements, 2nd edn. MGAGraphics Australia 2007.
19. Perrier A, Roy PM, Sanchez O et al. Multidetector-row computed tomography in suspected pulmonary embolism. N Engl J Med 2005 352 : 1760 68.
20. Quiroz R, Kucher N, Schoepf UJ, Kipfmueller F, Solomon SD, Costello P et al. Right ventricular enlargement on chest computed tomography: prognostic role in acute pulmonary embolism. Circulation 2004 109 : 2401 4.
21. Fava M, Loyola S, Flores P, Huete I. Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism. J Vasc Interv Radiol 1997 8 : 261 6.
22. Schmitz-Rode T, Kilbinger M, Günther RW. Simulated flow pattern in massive pulmonary embolism: significance for selective intrapulmonary thrombolysis. Cardiovasc Intervent Radiol 1998 21 : 199 204.
23. Verstraete M, Miller GA, Bounameaux H, Charbonnier B, Colle JP, Lecorf G et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988 77 : 353 60.
24. Lapanun W, Walters DL, Mcarthy J, Burstow DJ. Major pulmonary embolism and shock. Persistent hypotension after thrombolysis treated with improvised mechanical fragmentation of thrombus. Med J Aust 2003 179 : 495 6.
25. Barba R, Marco J, Martin-Alvarez H, Rondon P, Fernandez- Capitan C, Garcia-Bragado F, Monreal M. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost 2005 3 : 856 62.
26. Wilson SJ, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 2001 31 : 42 8.
27. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringler KA, Antman EM. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003 146 : 33 41.
28. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997 337 : 688 98.
29. Kinney T. Update on inferior vena cava filters. J Vasc Interv Radiol 2003 14 : 425 40.
30. McNeil K, Dunning JD. Chronic thromboembolic pulmonary hypertension (CTEPH). Heart 2007 93 : 1152 8.
31. McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. Am J Cardiol 1971 28 : 288 94.
32. Remy-Jardin M, Louvegny S, Remy J, Artaud D, Deschildre F, Bauchart JJ et al. Acute central thromboembolic disease: post therapeutic follow-up with spiral CT angiography. Radiology 1997 203 : 173 80.
33. Ribeiro A, Lindmarker P, Johnsson H, Juhlin-Dannfelt A, Jorfeldt L. Pulmonary embolism. One-year follow-up with echocardiography Doppler and five-year survival analysis. Circulation 1999 99 : 1280 83.
34. Wartski M, Collignon MA. Incomplete recovery of lung perfusion after 3 months in patients with acute pulmonary embolism treated with antithrombotic agents. J Nucl Med 2000 41 : 1043 8.
35. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004 350 : 2257 64.
36. Gabbay E, Reed A, Williams TJ. Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006. Intern Med J 2007 37 : 38 48.
37. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. Sildenafil use in pulmonary arterial hypertension (SUPER) study group: sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005 353 : 2148 57.
38. Hughes RJ, Jais X, Bonderman D, Suntharalingam J, Humbert M, Lang I, Simonneau G, Pepke-Zapa J. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006 28 : 138 43.
39. Lang IM. Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and post-pulmonary endarterectomy pulmonary hypertension: a subgroup analysis of the randomised, placebo-controlled trial - BENEFiT. Clinical Trial Update II Session Number: 4505. ESC Congress updated 5 Sep 2007; cited 5 May 2008 Available from http://www.escardio.org/knowledge/congresses/ CongressReports/2007/hlctu/4505-lang-ctu2.htm